Global Tumor Embolization Devices Market Size 2024, Forecast To 2033
22 Jan, 2024
The tumor embolization devices market has exhibited rapid growth, climbing from $1.62 billion in 2023 to $1.82 billion in 2024, marking a 12.8% CAGR. Historical drivers include the prevalence of minimally invasive procedures, technological advancements, increased cancer incidence, and an aging population. Projections estimate ongoing rapid growth to $2.83 billion in 2028, with an 11.6% CAGR. Drivers include personalized medicine, combination therapies, image-guided embolization, and trends in innovations related to embolic agents, transarterial chemoembolization (TACE), palliative care, and image-guided procedures.
Global Tumor Embolization Devices Market Key Driver
The increasing number of cancer cases worldwide is expected to boost the tumor embolization devices market. In 2021, the USA witnessed 1.9 million new cancer cases and 608,570 cancer-related deaths. Lung, prostate, bowel, and female breast cancers collectively account for 43% of new cancer cases globally. The rising global cancer incidence is anticipated to drive demand for tumor embolization devices in the coming years.
Get A Free Sample Of The Global Tumor Embolization Devices Market ReportGlobal Tumor Embolization Devices Market Segments
The tumor embolization devices market covered in this report is segmented –
1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents
2) By Application: Cancer Tumors, Noncancerous Tumors
3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers
By Geography: The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the tumor embolization devices market in 2023. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in the tumor embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Tumor Embolization Devices Industry Players
Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Siemens Healthineers AG, Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Meril Life Sciences Pvt. Ltd., Kaneka Corporation, Imagion Biosystems Ltd., Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Monteris Medical Corporation, NeuWave Medical Inc., Neoprobe Corporation, OncoSec Medical Incorporated, Helomics Corporation, Hologic, Surefire Medical Inc., Varian Medical Systems Inc.
Get The Full Global Tumor Embolization Devices Market Report
Tumor Embolization Devices Market Overview
Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor.
Tumor Embolization Devices Global Market Report 2023 provides data on the global tumor embolization devices market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The tumor embolization devices market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.